Guidant Focused On Trend Thresholds Instead Of Preventable Deaths – Panel
This article was originally published in The Gray Sheet
Executive Summary
Guidant has relied too much on engineers and not enough on physicians in evaluating the postmarket performance of its implantable cardiac rhythm management products, making it possible for device problems to go unaddressed, according to an expert panel commissioned by the company
You may also be interested in...
House Democrats Hammer On Arguments Against FDA Pre-Emption
A Supreme Court ruling favoring federal pre-emption for PMA-approved devices will shift the financial burden of faulty devices from manufacturers to U.S. consumers and taxpayers, Congressional Democrats argue
House Democrats Hammer On Arguments Against FDA Pre-Emption
A Supreme Court ruling favoring federal pre-emption for PMA-approved devices will shift the financial burden of faulty devices from manufacturers to U.S. consumers and taxpayers, Congressional Democrats argue
CDRH Unveils Postmarket Safety “Action Items”
FDA's plan to strengthen postmarket device safety by making better use of postmarket data includes modifying its organizational infrastructure, updating adverse event reporting practices and potentially increasing the use of fines for certain types of industry noncompliance